AREDS2: Insights Into Optimal Supplements for AMD

Charles C. Wykoff, MD, PhD


May 20, 2013

In This Article

The Age-Related Eye Disease Study 1

The Age-Related Eye Disease Study 1 (AREDS1) and AREDS2 were prospective randomized trials sponsored by the National Eye Institute, National Institutes of Health.[8,9]

AREDS1 enrolled 4757 patients and evaluated the ability of specific antioxidants (500 mg vitamin C and 400 IU vitamin E), minerals (80 mg zinc and 2 mg copper), and a carotenoid (15 mg beta-carotene) to slow the progression of AMD compared with placebo; together, these components make up the "AREDS1 formulation."

At 5 years, consumption of this formulation reduced the risk for advanced AMD by 25% in patients at high risk for progression.[8] This protective effect persisted through 10 years of follow-up.

In AREDS1, the 25% risk reduction was observed in patients with advanced AMD in 1 eye, or intermediate AMD, defined as extensive intermediate drusen in 1 or both eyes, 1 or more large drusen (≥125 µm, or about the diameter of a retinal vein where it crosses the margin of the optic nerve head) in at least 1 eye, or nonsubfoveal geographic atrophy in 1 eye.